Literature DB >> 25384436

Revising the link between proton-pump inhibitors and risk of acute myocardial infarction-a case-crossover analysis.

Aleksandra Turkiewicz1, Raquel Perez Vicente, Henrik Ohlsson, Patrik Tyden, Juan Merlo.   

Abstract

PURPOSE: The purpose of this study is to investigate if the prescription of proton-pump inhibitors (PPIs) was associated with a sudden risk of acute myocardial infarction (AMI) while controlling for time-invariant confounding by using a case-crossover design. An association might indicate that physicians take prodromal symptoms of myocardial ischaemia for dyspepsia.
METHODS: We applied a case-crossover design to investigate all AMI patients admitted to the hospital in the Skåne region, Sweden, between Oct 14, 2005 and Dec 31, 2006 and their PPI prescriptions and dispensations 3 months prior to the AMI onset. We retrieved the information about prescribed medication from the Swedish Drug Register containing individual information on all dispensed drugs prescribed in the outpatient care and dispensed in any of the Swedish pharmacies. Additionally, we stratified the analyses by history of AMI.
RESULTS: We identified 3490 AMI cases aged 40 to 90; 61 % were men. The odds ratio for AMI onset in those with a prescription of PPIs during a hazard period of 3 days compared to control periods was 1.36 (95 % confidence interval (CI) 0.82-2.25) in the whole study cohort and 1.66 (95 % CI 1.00-2.76) in those without history of AMI. The corresponding odds ratio (OR) based on the dispensation date (suggesting use of the drug) was 1.26 (95 % CI 0.92-1.72) and 1.29 (95 % CI 0.92-1.83), respectively.
CONCLUSIONS: In our opinion, the previously reported increase in risk of adverse cardiac events in patients using PPIs may reflect the fact that an AMI may be misinterpreted as dyspepsia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25384436     DOI: 10.1007/s00228-014-1779-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Clopidogrel with or without omeprazole in coronary artery disease.

Authors:  Deepak L Bhatt; Byron L Cryer; Charles F Contant; Marc Cohen; Angel Lanas; Thomas J Schnitzer; Thomas L Shook; Pablo Lapuerta; Mark A Goldsmith; Loren Laine; Benjamin M Scirica; Sabina A Murphy; Christopher P Cannon
Journal:  N Engl J Med       Date:  2010-10-06       Impact factor: 91.245

2.  Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies.

Authors:  David F Blackburn; Darcy A Lamb; Melanie M Mcleod; Dean T Eurich
Journal:  Pharmacotherapy       Date:  2010-10       Impact factor: 4.705

3.  Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers.

Authors:  J Merlo; U Lindblad; H Pessah-Rasmussen; B Hedblad; J Rastam; S O Isacsson; L Janzon; L Råstam
Journal:  Eur J Epidemiol       Date:  2000-03       Impact factor: 8.082

4.  Acute myocardial infarction: medicolegal issues.

Authors:  Sara Bird
Journal:  Aust Fam Physician       Date:  2005-06

5.  Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.

Authors:  Yohannes T Ghebremariam; Paea LePendu; Jerry C Lee; Daniel A Erlanson; Anna Slaviero; Nigam H Shah; James Leiper; John P Cooke
Journal:  Circulation       Date:  2013-07-03       Impact factor: 29.690

Review 6.  Should we use a case-crossover design?

Authors:  M Maclure; M A Mittleman
Journal:  Annu Rev Public Health       Date:  2000       Impact factor: 21.981

7.  A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.

Authors:  David N Juurlink; Tara Gomes; Dennis T Ko; Paul E Szmitko; Peter C Austin; Jack V Tu; David A Henry; Alex Kopp; Muhammad M Mamdani
Journal:  CMAJ       Date:  2009-01-28       Impact factor: 8.262

8.  Non-steroidal anti-inflammatory drugs as a risk factor for acute diarrhoea: a case crossover study.

Authors:  I Etienney; L Beaugerie; C Viboud; A Flahault
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

9.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

Authors:  P Michael Ho; Thomas M Maddox; Li Wang; Stephan D Fihn; Robert L Jesse; Eric D Peterson; John S Rumsfeld
Journal:  JAMA       Date:  2009-03-04       Impact factor: 56.272

10.  Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.

Authors:  Mette Charlot; Erik L Grove; Peter Riis Hansen; Jonas B Olesen; Ole Ahlehoff; Christian Selmer; Jesper Lindhardsen; Jan Kyst Madsen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  BMJ       Date:  2011-05-11
View more
  5 in total

Review 1.  Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors.

Authors:  Felice Schnoll-Sussman; Philip O Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

2.  Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study.

Authors:  Yen-Feng Wang; Yung-Tai Chen; Jiing-Chyuan Luo; Tzeng-Ji Chen; Jaw-Ching Wu; Shuu-Jiun Wang
Journal:  Am J Gastroenterol       Date:  2017-04-11       Impact factor: 10.864

Review 3.  How May Proton Pump Inhibitors Impair Cardiovascular Health?

Authors:  Roman A Sukhovershin; John P Cooke
Journal:  Am J Cardiovasc Drugs       Date:  2016-06       Impact factor: 3.571

Review 4.  The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.

Authors:  David A Johnson; Philip O Katz; David Armstrong; Henry Cohen; Brendan C Delaney; Colin W Howden; Peter Katelaris; Radu I Tutuian; Donald O Castell
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 5.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.